Gastric Adenocarcinoma Completed Phase 2 Trials for Ipilimumab (DB06186)

Back to Gastric Adenocarcinoma

Also known as: Adenocarcinoma gastric / Adenocarcinoma, Gastric / Gastric Adenocarcinomas / Adenocarcinoma of the Stomach / Stomach Adenocarcinoma / Gastric Cancer, Adenocarcinoma / Adenocarcinoma of stomach (disorder)

IndicationStatusPhase
DBCOND0030814 (Gastric Adenocarcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03409848
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaTreatment
NCT03647969
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerTreatment